.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,905,083

« Back to Dashboard

Details for Patent: 5,905,083

Title: Method of treating rheumatoid arthritis
Abstract:Disclosed are methods for rectifying or ameliorating abnormal responses of mammalian immune systems, such as rheumatoid arthritis. Also disclosed are methods for modifying normal responses of the mammalian immune system. Further disclosed are methods for accomplishing the foregoing by administering to a mammal a prolactin reducer and/or enhancer at a pre-determined time or times during a 24-hour period that results in modification of the mammal's abnormal prolactin profile so that it approaches or conforms to the prolactin profile of a young, healthy mammal of the same species (or to a standard profile generated from such individuals). Additionally, methods of upregulating or augmenting an immune response in a mammal are disclosed.
Inventor(s): Cincotta; Anthony H. (Andover, MA), Meier; Albert H. (Andover, MA)
Assignee: Ergo Science Incorporated (Charlestown, MA)
Filing Date:Jun 02, 1995
Application Number:08/459,114
Claims:1. In a method for treating a mammal suffering from rheumatoid arthritis by delivery to said subject a therapeutically effective amount of a prolactin reducer, wherein the improvement comprises:

confining the delivery of said prolactin reducer to the period during or up to three hours prior to the time interval of day at which the serum prolactin concentration of a lean, healthy mammal of the same sex and species is low.

2. A method for treating a mammal suffering from rheumatoid arthritis, comprising:

administering to said mammal a therapeutically effective amount of a prolactin reducer in a dosage regimen under which the delivery of said prolactin reducer is confined to the period during or up to three hours prior to the time of day at which the serum prolactin concentration of a young, healthy mammal of the same sex and species is low.

3. A method according to claim 1 in which the time of delivery of said prolactin reducer is confined to the period from between about 05:00 h and 13:00 h.

4. A method according to claim 2 in which the time of delivery of said prolactin reducer is confined to the period from between about 05:00 h and 13:00 h.

5. A method according to claim 1 in which said prolactin reducer is bromocriptine.

6. A method according to claim 2 in which said prolactin reducer is bromocriptine.

7. A method according to claim 5 wherein said bromocriptine is administered in an amount between about 3 and about 40 micrograms per kilogram of body weight per day.

8. A method according to claim 6 wherein said bromocriptine is administered in an amount between about 3 and about 40 micrograms per kilogram of body weight per day.

9. The method of claim 1 wherein said prolactin reducer is administered daily for at least 10 days.

10. The method of claim 2 wherein said prolactin reducer is administered daily for at least 10 days.

11. The method of claim 1 wherein said mammal is a human.

12. The method of claim 2 wherein said mammal is a human.

13. The method of claim 9 wherein said mammal is a human.

14. The method of claim 10 wherein said mammal is a human.

15. A method according to claim 3 in which the time of delivery of said prolactin reducer is confined to the period from between about 05:00 h and 10:30 h.

16. A method according to claim 4 in which the time of delivery of said prolactin reducer is confined to the period from between about 05:00 h and 10:30 h.

17. A method for treating a human suffering from rheumatoid arthritis, comprising:

administering to said human a therapeutically effective amount of a prolactin reducer in a dosage regimen under which the delivery of said prolactin reducer is confined to the period from between 05:00 h and 13:00 h.

18. A method of claim 17, wherein said prolactin reducer is delivered to said human at between 05:00 h and 10:30 h.

19. In a method for treating a human suffering from rheumatoid arthritis by delivery to said human a therapeutically effective amount of a prolactin reducer, wherein the improvement comprises:

confining delivery of said prolactin reducer to the period from between 05:00 h and 13:00 h.

20. An improvement according to claim 19, wherein said prolactin reducer is delivered to said human at between 05:00 h and 10:30 h.

21. A method of claim 17, wherein said prolactin reducer is bromocriptine.

22. A method of claim 18, wherein said prolactin reducer is bromocriptine.

23. A method of claim 19, wherein said prolactin reducer is bromocriptine.

24. A method of claim 20, wherein said prolactin reducer is bromocriptine.

25. The method of claim 21 wherein said bromocriptine amount is within the range of 0.8 to 8.0 mg/patient/day.

26. The method of claim 22 wherein said bromocriptine amount is within the range of 0.8 to 8.0 mg/patient/day.

27. The method of claim 23 wherein said bromocriptine amount is within the range of 0.8 to 8.0 mg/patient/day.

28. The method of claim 24 wherein said bromocriptine amount is within the range of 0.8 to 8.0 mg/patient/day.

29. The method of claim 25 wherein said bromocriptine is administered daily for at least 10 days.

30. The method of claim 26 wherein said bromocriptine is administered daily for at least 10 days.

31. The method of claim 27 wherein said biomocriptine is administered daily for at least 10 days.

32. The method of claim 28 wherein said bromocriptine is administered daily for at least 10 days.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc